Myriad Licenses Rights to Pancreatic Cancer Gene Patents | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market Thursday that it has licensed exclusive rights from Johns Hopkins University to patents covering a gene related to pancreatic cancer.

The Salt Lake City-based molecular diagnostics firm said the worldwide, exclusive license covers rights to patents covering mutations in the PALB2 gene, which have been found to increase an individual's risk for developing pancreatic cancer. The company hopes to launch a new predictive test next year containing markers for hereditary pancreatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.